Position in BBIO
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,849,178
+$125,921 QoQ
Shares Held
65,300
+5.7% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GABELLI FUNDS LLC holds $96,689,277 across 29 Biotechnology names. BBIO ranks #6 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
195,900 | $22,493,238 | |
| 2 | TERN |
Terns Pharmaceuticals, Inc.
|
271,857 | $14,332,301 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
|
942,650 | $13,630,719 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
321,200 | $12,921,876 | |
| 5 | DAWN |
Day One Biopharmaceuticals, Inc.
|
464,097 | $9,950,239 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
This page
|
65,300 | $4,849,178 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,920 | $3,536,596 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
46,200 | $2,985,906 |
All Filings in BBIO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,849,178 | 65,300 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,723,257 | 61,750 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $3,804,605 | 73,250 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $3,184,525 | 73,750 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,540,895 | 73,500 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $2,016,840 | 73,500 | Shares | Sole | 2025-02-13 | |
| 2021-09-30 | $281,220 | 6,000 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $518,160 | 8,500 | Shares | Sole | 2021-08-13 | |
| 2021-03-31 | $782,320 | 12,700 | Shares | Sole | 2021-05-14 | |
| No filing history on record for this holder in this stock. | ||||||